Puma Other Current Liab vs Retained Earnings Total Equity Analysis
PBYI Stock | USD 4.01 0.01 0.25% |
Puma Biotechnology financial indicator trend analysis is much more than just breaking down Puma Biotechnology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Puma Biotechnology is a good investment. Please check the relationship between Puma Biotechnology Other Current Liab and its Retained Earnings Total Equity accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.
Other Current Liab vs Retained Earnings Total Equity
Other Current Liab vs Retained Earnings Total Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Puma Biotechnology Other Current Liab account and Retained Earnings Total Equity. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Puma Biotechnology's Other Current Liab and Retained Earnings Total Equity is -0.53. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Retained Earnings Total Equity in the same time period over historical financial statements of Puma Biotechnology, assuming nothing else is changed. The correlation between historical values of Puma Biotechnology's Other Current Liab and Retained Earnings Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of Puma Biotechnology are associated (or correlated) with its Retained Earnings Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings Total Equity has no effect on the direction of Other Current Liab i.e., Puma Biotechnology's Other Current Liab and Retained Earnings Total Equity go up and down completely randomly.
Correlation Coefficient | -0.53 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Other Current Liab
Retained Earnings Total Equity
The portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt.Most indicators from Puma Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Puma Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.As of now, Puma Biotechnology's Issuance Of Capital Stock is increasing as compared to previous years. The Puma Biotechnology's current Enterprise Value Over EBITDA is estimated to increase to 5.42, while Selling General Administrative is projected to decrease to under 65.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 10.6M | 8.9M | 10.2M | 9.1M | Interest Income | 160K | 813K | 2.4M | 1.5M |
Puma Biotechnology fundamental ratios Correlations
Click cells to compare fundamentals
Puma Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Puma Biotechnology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 234.9M | 244.2M | 226.6M | 222.1M | 230.5M | 165.1M | |
Total Stockholder Equity | 17.5M | (6M) | (2.4M) | 21.6M | 53.4M | 63.0M | |
Net Debt | 60.2M | 35.7M | 53.5M | 38.1M | 26.9M | 28.3M | |
Cash | 60M | 85.3M | 63.1M | 76.2M | 84.6M | 68.5M | |
Cash And Short Term Investments | 60M | 85.3M | 63.1M | 76.2M | 95.9M | 71.9M | |
Common Stock Shares Outstanding | 38.8M | 39.6M | 40.6M | 44.9M | 47.6M | 32.7M | |
Liabilities And Stockholders Equity | 234.9M | 244.2M | 226.6M | 222.1M | 230.5M | 165.1M | |
Other Stockholder Equity | 1.3B | 1.3B | 1.4B | 1.4B | 1.4B | 762.9M | |
Total Liab | 217.4M | 250.2M | 229.0M | 200.5M | 177.1M | 108.6M | |
Total Current Assets | 166.3M | 146.1M | 140.0M | 134.3M | 156.2M | 127.0M | |
Total Current Liabilities | 90.8M | 114.3M | 109.6M | 77.5M | 99.4M | 56.7M | |
Retained Earnings | (1.3B) | (1.3B) | (1.4B) | (1.4B) | (1.3B) | (1.3B) | |
Accounts Payable | 19.2M | 12.1M | 11.2M | 6.4M | 6.9M | 12.3M | |
Other Current Liab | 69.0M | 2.5M | 2.3M | 66.9M | 53.7M | 30.7M | |
Other Liab | 9M | 32.3M | 6.4M | 12.8M | 14.7M | 7.6M | |
Net Tangible Assets | (23.0M) | (80.1M) | (68.6M) | 21.6M | 19.4M | 18.5M | |
Property Plant And Equipment Net | 21.8M | 18.9M | 15.8M | 12.5M | 8.6M | 8.4M | |
Non Current Assets Total | 68.6M | 98.1M | 86.6M | 87.8M | 74.3M | 49.8M | |
Non Currrent Assets Other | 6.3M | 5.1M | 4.7M | 4.7M | 2.7M | 5.0M | |
Other Assets | 6.3M | 5.1M | 4.7M | 4.7M | 1.0 | 0.95 | |
Long Term Debt | 95.0M | 84.0M | 97.1M | 98.3M | 65.7M | 54.2M | |
Retained Earnings Total Equity | (1.3B) | (1.3B) | (1.4B) | (1.4B) | (1.2B) | (1.3B) | |
Short Term Investments | 51.6M | 8.1M | 19.0M | 4.9M | 11.4M | 10.8M | |
Non Current Liabilities Total | 126.6M | 135.9M | 119.4M | 123.0M | 77.7M | 68.1M | |
Capital Surpluse | 1.3B | 1.3B | 1.4B | 1.4B | 1.6B | 952.6M | |
Inventory | 3.2M | 3.5M | 7.1M | 4.5M | 7.1M | 8.2M | |
Other Current Assets | 2.7M | 2.7M | 2.6M | 2.0M | 4.7M | 4.8M | |
Deferred Long Term Liab | 5.8M | 868K | 955K | 743K | 854.5K | 811.7K | |
Property Plant And Equipment Gross | 21.8M | 18.9M | 22.6M | 1.1M | 16.3M | 8.7M | |
Accumulated Other Comprehensive Income | (12K) | 62K | 0.0 | (2K) | (4K) | (4.2K) | |
Intangible Assets | 40.5M | 74.1M | 66.1M | 70.6M | 60.9M | 34.3M | |
Property Plant Equipment | 3.3M | 2.5M | 15.8M | 1.1M | 1.3M | 1.3M | |
Net Receivables | 28.9M | 25.5M | 32.5M | 42.3M | 48.5M | 25.5M | |
Short Long Term Debt Total | 120.2M | 121.0M | 116.6M | 114.3M | 111.5M | 123.2M | |
Long Term Debt Total | 151.9M | 95.0M | 84.0M | 97.1M | 111.7M | 104.8M | |
Net Invested Capital | 112.4M | 92.4M | 94.6M | 119.9M | 153.1M | 135.2M | |
Net Working Capital | 75.5M | 31.9M | 30.4M | 56.8M | 56.8M | 49.8M |
Currently Active Assets on Macroaxis
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Puma Stock analysis
When running Puma Biotechnology's price analysis, check to measure Puma Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Puma Biotechnology is operating at the current time. Most of Puma Biotechnology's value examination focuses on studying past and present price action to predict the probability of Puma Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Puma Biotechnology's price. Additionally, you may evaluate how the addition of Puma Biotechnology to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Puma Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.78) | Earnings Share 0.32 | Revenue Per Share 4.769 | Quarterly Revenue Growth (0.17) | Return On Assets 0.081 |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.